Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo

摘要: A composite index for estimating improvement in individual rheumatoid arthritis (RA) patients during trials of slow-acting, disease-modifying antirheumatic drugs (DMARDs) was developed by analyzing the responses 130 placebo-treated participants Cooperative Systematic Studies Rheumatic Diseases studies. If 4 6 selected measures were required (by greater than or equal to 20% morning stiffness, Westergren erythrocyte sedimentation rate, joint pain/tenderness score, and swelling 2 grades on a 5-grade scale, from grade 1 patient's physician's overall assessments current disease severity), few qualified as improved, whereas significantly more DMARD-treated demonstrated improvement. The proposed appears be useful probability that an RA patient will improve if taking placebo DMARD trial, may tool analysis